MAPT and Alzheimer disease: Over the past 20 years, many efforts have been made to modify tau and Aβ pathologies of AD by reducing the cytotoxicity of tau, preventing the aggregation of Aβ, and enhancing the clearance of Aβ, etc. [1, 4].